"Abstract
... To date, there are no published studies on the biodistribution, cellular uptake, endosomal escape, translation rates, functional half-life and inactivation kinetics of synthetic mRNA, rates and duration of vaccine-induced antigen expression in different cell types. Furthermore, despite the assumption that there is no possibility of genomic integration of therapeutic synthetic mRNA, only one recent study has examined interactions between vaccine mRNA and the genome of transfected cells, and reported that an endogenous retrotransposon, LINE-1 is unsilenced following mRNA entry to the cell, leading to reverse transcription of full length vaccine mRNA sequences, and nuclear entry. This finding should be a major safety concern, given the possibility of synthetic mRNA-driven epigenetic and genomic modifications arising...
The hypothesis
We hypothesize that in... susceptible individuals, clearance of nms [nucleoside-modified synthetic]-mRNAs is hampered. Sustained presence of nms-mRNA in the cytoplasm deregulates endogenous transposable elements (TEs)... Activated TEs increase the risk of insertional mutagenesis of the retrotranscribed vaccine mRNA, which can disrupt coding regions, enhance the risk of mutations in tumour suppressor genes, and lead to sustained DNA damage.
Consequences and discussion
... If our hypothesis were to be confirmed, the implications for public health would be staggering and appalling in the context of the mass-scale COVID-19 vaccination already taking place, particularly if the nms-mRNA enters brain, bone marrow, and – if already present in the vaccinee – cancerous or pre-cancerous cells, or if the vaccine is administered to females early in their pregnancy and the nms-mRNA transfects embryonic cells."
https://pmc.ncbi.nlm.nih.gov/articles/PMC9876036/
© 2023 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.